Month: March 2026

Novaturas Group announces a change in its executive team. As of March 27, Chief Financial Officer Auksė Kriaučiūnaitė is stepping down from her position. The company is currently conducting a search for a new candidate. “We are grateful to Auksė for her significant contribution and for taking on the responsibility of leading the finance team during a particularly dynamic period. We are glad to have worked together over these years and wish her the best of success in her future career,” says Novaturas CEO Ieva Galvydienė. The company is currently searching for a new Chief Financial Officer who will oversee operations across Lithuania, Latvia, and Estonia. During the selection process, CFO responsibilities will be ensured through internal resources. About the company The Novaturas Group is a tour operator offering the widest range of travel...

Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) hastoday published its integrated Annual Report for 2025, including sustainabilityreporting and complete annual accounts with notes. The report is attached and available on the following website: https://arnarlax.is/investors/ For further information, please contact:CEO Bjørn HembreTel: +354 620 1936Email: bjorn@arnarlax.is Interim CFO Edvin AspliTel: +354 835 7800Email: edvinaspli@arnarlax.is Icelandic Salmon is dual-listed on the stock exchange market, both at the Euronext Growth in Oslo and NASDAQ First North in Reykjavík. The Group is the 100% owner of Arnarlax ehf, a farming company in Iceland with head office in Bíldudalur. The Group is fully integrated, from egg to fish delivered to customers in the market, with control over all parts of the value chain. See...

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offering, the “Equity Offering”). Zenas estimates that the aggregate net proceeds from the Convertible Notes Offering and the Equity Offering will be...

SAINT-BRUNO-DE-MONTARVILLE, Québec, March 26, 2026 (GLOBE NEWSWIRE) — Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) provided today an update regarding its sale and investment solicitation process (“SISP”) conducted under the supervision of the Superior Court of Québec (Commercial Division) (the “Court”) and Raymond Chabot Inc., as Court-appointed monitor of the Company (the “Monitor”) in connection with the restructuring proceedings (the “CCAA Proceedings”) of the Company and certain of its subsidiaries, Transport Paul-Émile Dubé Ltée, Le Groupe Resto-Achats Inc. and Norref Fisheries Quebec Inc., instituted on January 8, 2026, under the Companies’ Creditors Arrangement Act (Canada). The Company continues to make progress with its SISP with the assistance of the Monitor, and has accepted four binding offers for the substantial...

Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week Novo Nordisk expects to launch Awiqli® nationwide in the US in the second half of 2026.Bagsværd, Denmark, 27 March 2026 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes. The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient routines and preferences...

Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) — Vemanti Group, Inc. (“Vemanti” or the “Company”) (OTC: VMNT) today issues this statement regarding the ongoing investigation in Vietnam related to the ONUS Pro cryptocurrency platform (the “Platform”). The Company today learned of the indictments of Nhan (“Eric”) Vuong, Chairman of the Company’s Board of Directors, and Chien Tran, a member of the Company’s Board of Directors, through the official announcement by Vietnam’s Ministry of Public Security (the “MPS”) and Vietnamese news media, simultaneously with the general public. Prior to today, the Company had received no official communication from any authorities, law enforcement, or regulatory agencies in any jurisdiction regarding this matter. The Company...

HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that the Company has granted, in the aggregate, 477,535 restricted share units (“RSUs”) and 32,738 deferred share units (“DSUs”) to directors and officers of the Company. The RSUs and DSUs granted to directors are scheduled to vest on a one-third per annum basis over a three-year period. The RSUs granted to officers are based on a combination of time and performance with 50% of the RSUs vesting 1/3 on the anniversary of the grant date over a period of three years and 50% of the RSUs vesting on the third anniversary of the grant date subject to achievement of certain key performance indicators as established by the Company’s Board of Directors. Each vested RSU entitles the holder to receive one share of the Company’s common stock...